T. Pudlarz, N. Naoun, G. Beinse, D. Grazziotin-Soares, J.-P. Lot

Oncologie, Vol.21, No.1, pp. 53-68, 2019, DOI:10.3166/onco-2019-0036

Abstract In this special issue of Oncology, we have summarized the most relevant topics that were presented at the American Association for Cancer Research (AACR) meeting. Our purpose here is to give the readers a concise report of the presentations that warrant particular attention. This year 2019 in Atlanta, the AACR Annual Meeting program covered the latest discoveries across the spectrum of cancer research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions all over the world. It… More >

V. Massard, A. Harlé, L. Uwer, J.-L. Merlin

Oncologie, Vol.21, No.1, pp. 29-32, 2019, DOI:10.3166/onco-2019-0027

Abstract Acquired endocrine resistance remains one of the main obstacles in the treatment of estrogen receptor (ER) positive, HER2 negative advanced breast cancer. Recently, activating ESR1 gene mutations affecting the ligand-binding domain have been identified as a key mechanism in aromatase inhibitor (AI) resistance. These mutations can be detected on histological samples or circulating tumour DNA, using PCRbased assays or next-generation sequencing. They induce a constitutive activation of ER, leading to acquired resistance to AI; tamoxifen, fulvestrant and targeted therapies against mTOR or CDK4/6 retain their efficacy. The use of monitoring ESR1 mutations in clinical practice is still to be defined.… More >

Hyeong Won Yu¹, Muhammad Afzal², Maqbool Hussain², Hyungju Kwon³, Young Joo Park⁴, June Young Choi^1,*, Kyu Eun Lee⁵

CMC-Computers, Materials & Continua, Vol.67, No.1, pp. 1241-1251, 2021, DOI:10.32604/cmc.2021.014910

Abstract Advances in technology are enabling gene mutations in papillary thyroid carcinoma (PTC) to be analyzed and clinical outcomes, such as recurrence, to be predicted. To date, the most common genetic mutation in PTC is in BRAF kinase (BRAF). However, whether mutations in other genes coincide with those in BRAF remains to be clarified. The aim of this study was to find mutations in other genes that co-exist with mutated BRAF, and to analyze their frequency and clinical relevance in PTC. Clinical and genetic data were collected from 213 PTC patients with a total of 36,572 mutation sites in 735 genes.… More >

Yao SUN, Yao LI, Xin SUN, Qiong WU, Lei WANG^*

BIOCELL, Vol.44, No.1, pp. 117-126, 2020, DOI:10.32604/biocell.2020.08242

Abstract Phosphorylation is a common type of post-translational modification (PTM). It plays a vital role in many cellular processes. The reversible phosphorylation and dephosphorylation affect protein structures and proteinprotein interactions. Previously, we obtained five proteins that interact with ethylene-responsive factor (ERF) from the cDNA library of Populus simonii x Populus nigra. To further investigate the effect of dephosphorylation of PsnERF on its protein binding ability, we generated different phosphorylation states of PsnERF and demonstrated their protein binding capacity by the yeast two-hybrid assay (Y2H). The secondary structures and 3D structures of PsnERF, ERFm, TrunERF, and psnerf^197/198/202a were predicted by homology modeling.… More >

López Colomba E¹, A Prina², S Griffa¹, AN Ribotta¹, E Carloni¹, E Tommasino¹, C Luna¹, E Biderbost¹, K Grunberg¹

Phyton-International Journal of Experimental Botany, Vol.80, pp. 59-64, 2011, DOI:10.32604/phyton.2011.80.059

Abstract Cenchrus ciliaris L., a forage grass of wide distribution in the north-west of Argentina, is a tetraploid (4x = 36) and obligate apomictic species. One way of obtaining novel germplasm is by induced mutations. In this work, physical and chemical mutations are combined with in vitro selection procedures seeking for new germplasm, with emphasis on salinity and drought tolerance. Mature seeds of Cenchrus ciliaris L. cv Biloela were subjected to treatments with X rays (400 Gy) and ethyl methanesulphonate (EMS) water solution (5.5 mM for 24 h). To perform in vitro selection, after 7 days of EMS or X rays… More >